Comparing two bevacizumab doses with chemotherapy for ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This Phase 2 trial compares two standard doses of bevacizumab (a medicine that targets blood supply to tumors) added to chemotherapy in people with advanced ovarian, fallopian tube, or primary peritoneal cancer. It’s for ovarian cancers that have returned or grown again soon after prior platinum chemotherapy, with the goal of improving control of the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have epithelial ovarian cancer (or fallopian tube or primary peritoneal cancer) confirmed by pathology.
- Your cancer is advanced, metastatic, recurrent, or cannot be fully removed, and you have no curative (curing) option.
- Your cancer is “platinum resistant,” meaning it progressed within 6 months after a platinum chemotherapy treatment.
- You must have measurable (measurable on scans or exam) visible cancer for response tracking, and scans must be recent (within 28 days).
- You must have never taken bevacizumab or any similar “anti-angiogenesis” cancer drug before.
- You need to be 18+ and able to consent and follow visits; your health status should be moderate (ECOG 0–2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests a treatment made of an investigational gene-based drug plus standard “platinum” chemotherapy and bevacizumab, compared with standard chemotherapy and bevacizumab. It’s for ovarian/fallopian tube/primary peritoneal cancers that have not responded to platinum chemotherapy or came back quickly.
This trial tests adding trastuzumab to standard maintenance therapy with bevacizumab for patients with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see if the combination helps keep the cancer from growing longer.
This trial is testing a new drug, LBL-024, combined with chemotherapy (with or without a targeted therapy called bevacizumab) for ovarian cancer that has stopped responding to standard platinum-based treatment. The goal is to see if this combination can effectively shrink tumors and slow the disease's progression.
This trial tests a new combination therapy (SYS6041 plus another drug) for women with recurrent ovarian cancer. It is for those whose cancer has come back after platinum chemotherapy, and who have not had too many previous treatments. The goal is to see if the combination can shrink tumors or slow disease progression.
This study tests a new drug (INCB123667) given as a pill, compared to standard chemotherapy, for people whose ovarian cancer has stopped responding to platinum-based treatments and whose tumor has high levels of a protein called Cyclin E1. The goal is to see if the new drug works better than standard chemo for this specific type of cancer.
This trial tests whether adding trastuzumab deruxtecan to standard maintenance therapy with bevacizumab works better than bevacizumab alone for people with advanced ovarian cancer that has the HER2 protein. It is for those who have finished initial chemotherapy plus bevacizumab and are now starting maintenance treatment.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.